# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0001104659-23-031570
**Filing Date:** 2023-3
**Character Count:** 2665
**Document Hash:** 1d34c69b459a1ed0bcadcad3282ddcec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-031570.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001104659-23-031570

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 981034922
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36288
- **FILM NUMBER:** 23725896

**BUSINESS ADDRESS:**
- **STREET 1:** 24 WEST 40TH STREET
- **STREET 2:** 8TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** (646) 350-0702

**MAIL ADDRESS:**
- **STREET 1:** 24 WEST 40TH STREET
- **STREET 2:** 8TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: March 2023

Commission file number: 001-36288

<u>AKARI THERAPEUTICS, PLC</u>

(Translation of registrant's name into English)

<u>75/76 Wimpole Street</u>

<u>London W1G 9RT</u>

<u>United Kingdom</u>

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Akari Therapeutics, Plc, (the "Company"), has been made aware that, on March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank, Santa Clara, California ("SVB") and appointed the Federal Deposit Insurance Corporation as receiver of the bank.

The Company does not hold any deposits or securities at SVB and has no accounts at SVB.

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| <br> Akari Therapeutics, Plc | <br> Akari Therapeutics, Plc |
| (Registrant) | (Registrant) |
| By: | /s/ Rachelle Jacques |
| Name: <br> Title: | Rachelle Jacques<br> President and Chief Executive Officer |

---

Date: March 13, 2023